UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Every time our body encounters a new disease-causing agent, a crucial defense system called adaptive immunity comes into play ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

T cells are central mediators of autoimmune disease pathogenesis, yet their functional states are not defined solely by antigen recognition or canonical ...

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...